drugset
Drugs / Mapracorat
last change Oct 2013 re-read 2 minutes ago

Mapracorat

also known as ZK 245186 · BOL-303242-X · BAY 86-5319

Small molecule targets NR3C1 via activation

Developed for
cataract · atopic eczema · atopic conjunctivitis · corneal disorder · dry eye syndrome · psoriasis
Investigated by
Bausch & Lomb Incorporated · Bayer

Trials 11 · a red edge is where a trial was stopped

today NCT01736462 · Ph 1 NCT03399526 · Ph 1 NCT01591655 · Ph 3 NCT01591161 · Ph 3 NCT01408511 · Ph 2 NCT01407510 · Ph 2 NCT01298752 · Ph 3 NCT01289431 · Ph 2 NCT01230125 · Ph 3 NCT01163643 · Ph 2 NCT00905450 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT03399526 Feb → May 2013 psoriasis Bayer Completed No outcome recorded
Phase 1 NCT01736462 Feb → Jul 2013 corneal disorder Bausch & Lomb Incorporated Completed No outcome recorded
Phase 25 trials
Phase 2 NCT01408511 Jul → Dec 2011 atopic eczema Bayer Completed No outcome recorded
Phase 2 NCT01407510 May → Sep 2011 atopic eczema Bayer Completed No outcome recorded
Phase 2 NCT01289431 Feb → Apr 2011 atopic conjunctivitis Bausch & Lomb Incorporated Completed No outcome recorded
Phase 2 NCT01163643 Jul 2010 → Jun 2011 dry eye syndrome Bausch & Lomb Incorporated Completed No outcome recorded
Phase 2 NCT00905450 Jun 2009 → Mar 2010 cataract Bausch & Lomb Incorporated Completed No outcome recorded
Phase 34 trials
Phase 3 NCT01591655 Jul 2012 → Sep 2013 cataract Bausch & Lomb Incorporated Completed No outcome recorded
Phase 3 NCT01591161 Jul 2012 → Jun 2013 cataract Bausch & Lomb Incorporated Completed No outcome recorded
Phase 3 NCT01298752 Feb → Sep 2011 cataract Bausch & Lomb Incorporated Terminated No outcome recorded
Phase 3 NCT01230125 Nov 2010 → Jun 2011 cataract Bausch & Lomb Incorporated Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01359787 Comparator May → Sep 2011 atopic eczema Bayer Completed No outcome recorded
Phase 2 NCT01228513 Comparator Nov 2010 → Jul 2011 atopic eczema Bayer Completed No outcome recorded
Phase 2 NCT00944632 Comparator Jul 2009 → Sep 2010 atopic eczema Bayer Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as Mapracorat “BOL-303242-X (Mapracorat)” NCT00905450 ↗
10

NCT01408511 ↗

NCT01591655 ↗

NCT01230125 ↗

NCT01298752 ↗

NCT01359787 ↗

NCT01736462 ↗

NCT01591161 ↗

NCT03399526 ↗

NCT01289431 ↗

NCT01407510 ↗
Known as BAY 86-5319 “Mapracorat (ZK 245186, BAY 86-5319)” NCT03399526 ↗
Known as BOL-303242-X ClinicalTrials.gov intervention name — accepted as the source's own label NCT01163643 ↗
1

NCT00905450 ↗
Known as ZK 245186 “Mapracorat (ZK 245186, BAY 86-5319)” NCT03399526 ↗
2

NCT00944632 ↗

NCT01228513 ↗
Action Activate “Glucocorticoid receptor agonist” CHEMBL2103876 ↗
Modality Small molecule — CHEMBL2103876 ↗
Route Topical “Once daily topical non-occlusive application for up to 4 weeks” NCT00944632 ↗
Target NR3C1 “Glucocorticoid receptor agonist” CHEMBL2103876 ↗